These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33714289)

  • 1. Evaluation of risk factors for nephrotoxicity associated with high-dose vancomycin in Japanese patients.
    Higashi T; Tsukamoto H; Kodawara T; Igarashi T; Watanabe K; Yano R; Iwasaki H; Goto N
    Pharmazie; 2021 Feb; 76(2):114-118. PubMed ID: 33714289
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.
    Burgess LD; Drew RH
    Pharmacotherapy; 2014 Jul; 34(7):670-6. PubMed ID: 24855041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion.
    Mousavi M; Zapolskaya T; Scipione MR; Louie E; Papadopoulos J; Dubrovskaya Y
    Pharmacotherapy; 2017 Mar; 37(3):379-385. PubMed ID: 28079263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose intravenous vancomycin therapy and the risk of nephrotoxicity.
    Rostas SE; Kubiak DW; Calderwood MS
    Clin Ther; 2014 Jul; 36(7):1098-101. PubMed ID: 24931573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study.
    Mullins BP; Kramer CJ; Bartel BJ; Catlin JS; Gilder RE
    Ann Pharmacother; 2018 Jul; 52(7):639-644. PubMed ID: 29442542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study.
    Blair K; Covington EW
    Ann Pharmacother; 2020 Nov; 54(11):1096-1101. PubMed ID: 32406243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.
    Gomes DM; Smotherman C; Birch A; Dupree L; Della Vecchia BJ; Kraemer DF; Jankowski CA
    Pharmacotherapy; 2014 Jul; 34(7):662-9. PubMed ID: 24753221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin-Associated Nephrotoxicity: The Obesity Factor.
    Davies SW; Efird JT; Guidry CA; Dietch ZC; Willis RN; Shah PM; Hennessy SA; Sawyer RG
    Surg Infect (Larchmt); 2015 Dec; 16(6):684-93. PubMed ID: 26324996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of an Antimicrobial Stewardship Program on Patient Safety in Veterans Prescribed Vancomycin.
    Fodero KE; Horey AL; Krajewski MP; Ruh CA; Sellick JA; Mergenhagen KA
    Clin Ther; 2016 Mar; 38(3):494-502. PubMed ID: 26831569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of area under the concentration-time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury.
    Muklewicz JD; Steuber TD; Edwards JD
    Int J Antimicrob Agents; 2021 Jan; 57(1):106234. PubMed ID: 33232734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.
    Lodise TP; Lomaestro B; Graves J; Drusano GL
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1330-6. PubMed ID: 18227177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous Vancomycin Associated With the Development of Nephrotoxicity in Patients With Class III Obesity.
    Choi YC; Saw S; Soliman D; Bingham AL; Pontiggia L; Hunter K; Chuang L; Siemianowski LA; Ereshefsky B; Hollands JM
    Ann Pharmacother; 2017 Nov; 51(11):937-944. PubMed ID: 28709394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam Compared to Vancomycin and Meropenem or Doripenem: A Retrospective Cohort Study].
    Ide N; Sato S; Sawaguchi K
    Yakugaku Zasshi; 2019; 139(12):1609-1614. PubMed ID: 31787651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem.
    Robertson AD; Li C; Hammond DA; Dickey TA
    Pharmacotherapy; 2018 Dec; 38(12):1184-1193. PubMed ID: 30175410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Nephrotoxicity of Vancomycin.
    Filippone EJ; Kraft WK; Farber JL
    Clin Pharmacol Ther; 2017 Sep; 102(3):459-469. PubMed ID: 28474732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Top Guns: The "Maverick" and "Goose" of Empiric Therapy.
    Davies SW; Efird JT; Guidry CA; Dietch ZC; Willis RN; Shah PM; Sawyer RG
    Surg Infect (Larchmt); 2016 Feb; 17(1):38-47. PubMed ID: 26484854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of body weight-based vancomycin therapy and the incidence of nephrotoxicity: a retrospective study in the northwest of China.
    Dong MH; Wang JW; Wu Y; Chen BY; Yu M; Wen AD
    Int J Infect Dis; 2015 Aug; 37():125-8. PubMed ID: 26159843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.
    Rutter WC; Cox JN; Martin CA; Burgess DR; Burgess DS
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy.
    Carreno J; Smiraglia T; Hunter C; Tobin E; Lomaestro B
    Int J Antimicrob Agents; 2018 Nov; 52(5):643-650. PubMed ID: 30103003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.
    Finch NA; Zasowski EJ; Murray KP; Mynatt RP; Zhao JJ; Yost R; Pogue JM; Rybak MJ
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.